Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
An estimate of research and development costs for new therapeutic agents based on publicly available data is provided to reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations. Expand
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
It is indicated that there are opportunities for cost savings in generic drug markets in Europe and the United States, and governments should apply coherent supply‐ and demand‐side policies inGeneric drug markets. Expand
Early chronic kidney disease: diagnosis, management and models of care
- O. Wouters, D. O'donoghue, J. Ritchie, P. Kanavos, A. Narva
- Nature Reviews Nephrology
- 1 August 2015
Which early CKD interventions are appropriate, the optimum time to provide clinical care, and the most suitable model of care to adopt are discussed. Expand
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
A dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries is developed. Expand
Pharmaceutical regulation in 15 European countries review.
Investigation of a broad range of regulatory measures, spanning marketing authorization to generic substitution and resulting price levels in a sample of 16 European health systems finds no definitive evidence has yet been produced on the effects of different cost-containment measures on patient outcomes. Expand
Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval
Cumulative evidence on agents with accelerated approvals has major limitations and there appears to be a tendency for therapeutic agents receiving accelerated approval to quickly become an integral component of standard treatment, despite potential shortcomings in their evidence base. Expand
Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform
In Cyprus, if the national health system is going to provide universal health coverage in a sustainable fashion, then the national government must address the current issues in the pharmaceutical sector, including high medicine prices, underuse of generic medicines and high out-of-pocket drug spending. Expand
Resource Planning for Neglected Tropical Disease (NTD) Control Programs: Feasibility Study of the Tool for Integrated Planning and Costing (TIPAC)
The Tool for Integrated Planning and Costing (TIPAC), a versatile planning and costing instrument, is designed to be used by members of a NTD program at the national level and can be implemented at a subnational administrative level. Expand
An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review
There is substantial variation in the network meta-analysis literature and consensus among guidelines is needed to improve the methodological quality, transparency, and consistency of study conduct and reporting. Expand